مجله دانشکده پزشکی اصفهان (Mar 2022)

Up-regulation of SNHG5 Expression Level in Patients with Chronic Myeloid Leukemia Compared with Normal Individuals

  • Zahra Shahpouri-Arani,
  • Mohamad Reza Hajari,
  • Javad Mohammadi-Asl,
  • Najmaldin Saki

DOI
https://doi.org/10.48305/jims.2022.16290
Journal volume & issue
Vol. 40, no. 659
pp. 62 – 68

Abstract

Read online

Background: Chronic myeloid leukemia is a type of myeloproliferative malignancy that is associated with translocation between chromosomes 9 and 22 and accounts for approximately 15% of all leukemia. SNHGs are a subset of long non-coding RNAs that are considered to host small nuclear RNAs. SNHG5 is a regulatory factor in gene expression in various cancers, including chronic myeloid leukemia. The aim of this study was to evaluate and compare the expression level of SNHG5 in the peripheral blood sample of patients with chronic myeloid leukemia compared to normal individuals and then to evaluate SNHG5 as a potential biomarker in these patients. Methods: This study was conducted with a case-control design. First, the accuracy of chronic myeloid leukemia was confirmed using karyotype, molecular and cellular methods. After RNA extraction from white blood cells and cDNA synthesis, gene expression was measured using Real Time PCR. Finally, the data were statistically analyzed.Findings: Findings of this study showed that the expression level of SNHG5 in patients with chronic myeloid leukemia significantly increased compared to normal individuals (P < 0.001). Increased expression may indicate the potential role of this molecule in the development and progression of this cancer.Conclusion: The present study demonstrates the effective role of SNHG5 in the progression of chronic myeloid leukemia and can be investigated as a biomarker and potential therapeutic target in future studies

Keywords